about
Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsThe PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant SchizophreniaA Role for Estrogen in Schizophrenia: Clinical and Preclinical FindingsDopamine Receptors and NeurodegenerationKinase AKT controls innate immune cell development and functionAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)"Selfish spermatogonial selection": a novel mechanism for the association between advanced paternal age and neurodevelopmental disordersAdvanced fault diagnosis methods in molecular networksUnique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in RatsAntipsychotic-like effects of a neurotensin receptor type 1 agonist.Glycogen synthase kinase-3β inhibition in the medial prefrontal cortex mediates paradoxical amphetamine action in a mouse model of ADHD.Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3β pathway.Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia.Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.Bipolar disorder risk gene FOXO6 modulates negative symptoms in schizophrenia: a neuroimaging genetics studyPalmitic Acid-BSA enhances Amyloid-β production through GPR40-mediated dual pathways in neuronal cells: Involvement of the Akt/mTOR/HIF-1α and Akt/NF-κB pathwaysDisruption of Akt signaling decreases dopamine sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex.GSK-3 signaling in developing cortical neurons is essential for radial migration and dendritic orientation.Schizophrenia: an integrated sociodevelopmental-cognitive model.Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunctionNovel implications of Lingo-1 and its signaling partners in schizophreniaTranscriptome alterations of mitochondrial and coagulation function in schizophrenia by cortical sequencing analysis.Computational extraction of a neural molecular network through alternative splicing.Altered expression of mRNA profiles in blood of early-onset schizophrenia.Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats.Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex.PDK1-Akt pathway regulates radial neuronal migration and microtubules in the developing mouse neocortexChronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in ratsInvestigation of Dysregulation of Several MicroRNAs in Peripheral Blood of Schizophrenia PatientsAkting up in the GABA hypothesis of schizophrenia: Akt1 deficiency modulates GABAergic functions and hippocampus-dependent functions.Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in miceGlycogen synthase kinase 3 beta (GSK3β) at the tip of neuronal development and regeneration.A balancing Akt: How to fine-tune neuronal migration speed.Enhancement of NK cells proliferation and function by Shikonin.PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Developmental Inhibition of Gsk3 Rescues Behavioral and Neurophysiological Deficits in a Mouse Model of Schizophrenia Predisposition.Possible role of rare variants in Trace amine associated receptor 1 in schizophrenia.MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer.
P2860
Q26752602-BC96B3E0-8772-4399-A494-847FDC9A758EQ26766054-B1044453-8C86-48F2-9521-F4440A5B9971Q26773403-C93CB23A-8FA2-49A7-B867-B5E4C1BBF684Q26778420-B8F4C3CA-C6A6-4154-B52F-BDD18B7D99F0Q26783348-C5F4EB11-79E3-4CB0-AA49-01D851AAC8D6Q26826119-FC63BCD7-0484-45A9-9680-6AD81526E08AQ28080599-218C366C-36C6-41C2-8C47-BDD2566CC925Q28290020-9983F9A9-2A84-4DF4-B000-F3451F04AA3AQ28543582-2EE3FFBB-E548-4CB6-9B6A-71E74760CCD1Q28546441-350AABC9-3BF9-4B5F-8CF6-4B40F29F3F7EQ30356261-30701B20-A14F-48B0-B063-DA5ED902167FQ30414710-4F3D1B9F-2E3C-4ECE-86BD-9FF13013CED2Q30416840-AAD19998-20E6-42B5-AE21-00540FFD8B89Q30418674-A23AE114-A816-4EAB-AC57-A40913EEB5FFQ30465622-B27A0EE1-A0FD-4AD6-BAEC-B8ABC7D7B2C5Q33599296-7D7FDA26-3B88-4132-9B24-4D13E1BBB072Q33849216-AC76F8D5-BE9B-4B98-A18B-5A32DCB02122Q33893744-760E0052-37C2-4D22-AF5E-082BE4E3603CQ33943345-19D6416D-6E15-4A88-9E34-AE550C46EED5Q34023115-67194DF8-70E4-44F8-82C8-75C4D935CDFDQ34348224-5009D5F8-5E23-47C9-870C-AEBB1EB1C4A8Q34399243-4E41E537-663A-44FD-A6CF-6DBF6BFADBFFQ34913157-C8E100DB-4D82-43EB-9658-3ACC7F23C5FDQ35059883-04220BAD-AD45-4BC6-AC93-A331ECB6F418Q36432391-B566E2B4-A31C-4EC7-93D1-6A65EEC9AD1DQ36804007-EB2BDAF4-3898-4A0A-B11F-C666202A1AD2Q36846918-F6384A4F-8307-4C20-9483-694D36CBF6C5Q36932540-0B50828F-5C89-4689-853B-D8E6A7DA20DBQ36957186-A60DA6A5-AB34-468F-A8A0-0065E54B4275Q37111054-E51C1578-4D55-46AF-B76A-58C40EEF28E8Q37160621-99D7AA7F-9A46-471C-BF86-F6C79C6F031FQ37247909-2C924E0D-3268-4D25-9D4E-3DC6924A8671Q37686822-3196A23A-6BB1-43E9-9C9E-3804CA5AFC35Q38155462-CDBEE916-EC75-4272-B9BA-78D44897564FQ38557889-A54E1B23-9BFC-422D-8A9F-9AA9A2ECFCE7Q38711887-4132D8C0-11B5-4038-A806-AB49B31C9DD0Q38776236-2BA5BAC5-28E8-4AFE-BF8B-D8E47575B2A0Q38848153-65F506EC-A8E9-4D5D-88EC-65F4C234EA1DQ38939089-9DE59300-E1B1-461F-9930-7BE0FA338959Q39233657-2ECC5DE2-4A51-4C8C-B1F3-826FF085DBFD
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
AKT/GSK3 signaling pathway and schizophrenia
@ast
AKT/GSK3 signaling pathway and schizophrenia
@en
type
label
AKT/GSK3 signaling pathway and schizophrenia
@ast
AKT/GSK3 signaling pathway and schizophrenia
@en
prefLabel
AKT/GSK3 signaling pathway and schizophrenia
@ast
AKT/GSK3 signaling pathway and schizophrenia
@en
P2860
P356
P1476
AKT/GSK3 signaling pathway and schizophrenia
@en
P2093
Effat S Emamian
P2860
P356
10.3389/FNMOL.2012.00033
P577
2012-03-15T00:00:00Z